marijuana stocks

GW Pharmaceuticals (GWPH) Looks Good: Stock Up 13.1% – Tale of the Tape

GW Pharmaceuticals plc (GWPH) was a big mover last session with its shares rising over 13% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This breaks the recent trend of the company as the stock is now trading above the past one month’s volatile price range of $79.55 to $84.89.

This biopharmaceutical company has seen 2 positive estimate revisions in the last 60 days. The Zacks Consensus Estimate has also moved higher over the same period. This implies solid trading potential for the company. So make sure to keep an eye on this stock going ahead to see if Friday’s rally can turn into more strength down the road.

GW Pharmaceuticals currently holds a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.

Investors interested in the Med-Products industry may also consider Abaxis, Inc. (ABAX) which sports a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

$ATTBF Seeks Financing Solutions to Facilitate New Growth Initiative

Abattis Seeks Financing Solutions to Facilitate New Growth Initiative: Abattis Ends US$5…

$MJNE Co-CEO Adam Laufer to Present at Cannabis Webcast 12-18-14

MJ Holdings, Inc. to Present at Cannabis Investor Webcast Miami, FL, Dec.…

Cresco Labs Inc. (CRLBF) Announces Opening of 10th Pennsylvania Dispensary in Ambler

Cresco Labs Announces Opening of 10th Pennsylvania Dispensary in Ambler Cresco Labs…

$NTRR Joint Venture Begins Phase I of Testing New Topical Treatment

NTRR Joint Venture Begins Phase I of Testing New Topical Treatment Neutra…